Literature DB >> 21074196

Prognostic impact of muscular venous branch invasion in localized renal cell carcinoma cases.

Andrew Feifer1, Caroline Savage, Heidi Rayala, William Lowrance, Geoffrey Gotto, Preston Sprenkle, Amit Gupta, Jennifer Taylor, Melanie Bernstein, Adebowale Adeniran, Satish K Tickoo, Victor E Reuter, Paul Russo.   

Abstract

PURPOSE: Beginning with the 2002 American Joint Committee on Cancer staging system, renal sinus muscular venous branch invasion has prognostic equivalence with renal vein invasion in renal cell carcinoma cases. To validate this presumed equivalence we compared patients with isolated muscular venous branch invasion to those with renal vein invasion and those with no confirmed vascular invasion.
MATERIALS AND METHODS: From routine cataloging at our institution we identified 500 patients who underwent partial or radical nephrectomy from 2003 to 2008. After excluding patients with metastasis or noncortical renal cell carcinoma pathology we identified 85 with positive muscular venous branch invasion (+). The 259 patients with pT1-2 muscular venous branch (-) invasion and the 71 with renal vein (+) invasion served as comparison groups. We used a multivariate Cox model to control for tumor characteristics using the Kattan renal cell carcinoma nomogram.
RESULTS: On multivariate analysis the risk of recurrence in the pT1-2 muscular venous branch invasion (-) group was lower than in the muscular venous branch invasion (+) group (HR 0.06, 95% CI 0.02-0.18, p < 0.001). Patients with renal vein invasion (+) had a recurrence rate similar to that in those with muscular venous branch invasion (+) (HR 0.80, 95% CI 0.39-1.65, p = 0.6). The overall survival rate was higher in the muscular venous branch invasion (-) group than in the other groups.
CONCLUSIONS: Patients with muscular venous branch invasion have an outcome inferior to that in patients with pT1-2 disease. This confirms the adverse prognosis of muscular venous branch invasion and supports pathological up-staging. The prognosis of muscular venous branch invasion is similar to that of renal vein invasion, although we cannot exclude the possibility of a difference. Our findings underscore the importance of close patient followup and careful pathological assessment of the nephrectomy specimen.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21074196      PMCID: PMC3437930          DOI: 10.1016/j.juro.2010.08.084

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  25 in total

1.  Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?

Authors:  Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Eugene D Kwon; Igor Frank; R Houston Thompson; Michael L Blute
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?

Authors:  R Houston Thompson; Bradley C Leibovich; John C Cheville; Christine M Lohse; Igor Frank; Eugene D Kwon; Horst Zincke; Michael L Blute
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

3.  NCCN clinical practice guidelines in oncology: kidney cancer.

Authors:  Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
Journal:  J Natl Compr Canc Netw       Date:  2009-06       Impact factor: 11.908

4.  Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma.

Authors:  V Ficarra; R Righetti; A D'Amico; E Rubilotta; G Novella; G Malossini; G Mobilio
Journal:  Oncology       Date:  2001       Impact factor: 2.935

5.  Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy.

Authors:  R Houston Thompson; John C Cheville; Christine M Lohse; W Scott Webster; Horst Zincke; Eugene D Kwon; Igor Frank; Michael L Blute; Bradley C Leibovich
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

6.  Renal cell carcinoma and the renal sinus.

Authors:  David Grignon; Gladell P Paner
Journal:  Adv Anat Pathol       Date:  2007-03       Impact factor: 3.875

7.  Microvascular tumour invasion in renal cell carcinoma: the most important prognostic factor.

Authors:  Marcos F Dall'Oglio; Alberto A Antunes; Alvaro S Sarkis; Alexandre Crippa; Kátia R Leite; Antonio Marmo Lucon; Miguel Srougi
Journal:  BJU Int       Date:  2007-06-06       Impact factor: 5.588

8.  Reappraisal of T3N0/NxM0 renal cell carcinoma: significance of extent of fat invasion, renal vein invasion, and adrenal invasion.

Authors:  Soo Jin Jung; Jae Y Ro; Luan D Truong; Alberto G Ayala; Steven S Shen
Journal:  Hum Pathol       Date:  2008-07-24       Impact factor: 3.466

Review 9.  Current staging of renal cell carcinoma.

Authors:  Bradley C Leibovich; Allan J Pantuck; Matthew H T Bui; Ken Ryu-Han; Amnon Zisman; Robert Figlin; Arie Belldegrun
Journal:  Urol Clin North Am       Date:  2003-08       Impact factor: 2.241

10.  Impact of several histopathological prognosticators and local tumour extension on oncological outcome in pT3b/c N0M0 renal cell carcinoma.

Authors:  Frederik C Roos; Judith Weirich; Anja Victor; Amelie Elsässer; Walburgis Brenner; Stefan Biesterfeld; Christian Hampel; Joachim W Thüroff
Journal:  BJU Int       Date:  2009-03-11       Impact factor: 5.588

View more
  9 in total

1.  [Clinical and pathological analysis of small renal cell carcinoma].

Authors:  X P Zhang; Z X Huang; L P Yu; X W Zhang; Q Li; S J Liu; T Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

2.  Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.

Authors:  Ricardo A Rendon; Anil Kapoor; Rodney Breau; Michael Leveridge; Andrew Feifer; Peter C Black; Alan So
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

3.  Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma.

Authors:  Michael Chevinsky; Mariam Imnadze; Alexander Sankin; Andrew Winer; Roy Mano; Christopher Jakubowski; Joseph Mashni; Daniel D Sjoberg; Ying-Bei Chen; Satish K Tickoo; Victor E Reuter; A Ari Hakimi; Paul Russo
Journal:  J Urol       Date:  2015-02-09       Impact factor: 7.450

4.  The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma.

Authors:  Nick W Liu; James D Wren; Emily Vertosick; Justin K Lee; Nicholas E Power; Nicole E Benfante; Simon Y Kimm; Manjit S Bains; Daniel D Sjoberg; Paul Russo; Jonathan A Coleman
Journal:  J Urol       Date:  2015-09-10       Impact factor: 7.450

Review 5.  MRI phenotype in renal cancer: is it clinically relevant?

Authors:  Naomi Campbell; Andrew B Rosenkrantz; Ivan Pedrosa
Journal:  Top Magn Reson Imaging       Date:  2014-04

6.  Open mini-flank partial nephrectomy: an essential contemporary operation.

Authors:  Paul Russo; Roy Mano
Journal:  Korean J Urol       Date:  2014-09-05

7.  Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma.

Authors:  Mark W Ball; Michael A Gorin; Kelly T Harris; Kevin M Curtiss; George J Netto; Christian P Pavlovich; Phillip M Pierorazio; Mohamad E Allaf
Journal:  BJU Int       Date:  2015-11-14       Impact factor: 5.588

Review 8.  Extended lymph node dissection in robotic radical prostatectomy: Current status.

Authors:  Sameer Chopra; Mehrdad Alemozaffar; Inderbir Gill; Monish Aron
Journal:  Indian J Urol       Date:  2016 Apr-Jun

Review 9.  Management of Renal Cell Carcinoma-Current Practice in Sub-Saharan Africa.

Authors:  Ayun Cassell; Mohamed Jalloh; Bashir Yunusa; Medina Ndoye; Mouhamadou M Mbodji; Abdourahmane Diallo; Saint Charles Kouka; Issa Labou; Lamine Niang; Serigne M Gueye
Journal:  J Kidney Cancer VHL       Date:  2019-12-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.